Do analysts recommend BMEA or TXMD?

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 502.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biomea Fusion is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TXMD or BDTX?

Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 389.22%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Black Diamond Therapeutics 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73

Do analysts recommend KLRS or TXMD?

Kalaris Therapeutics currently has a consensus price target of $15.60, indicating a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

TherapeuticsMD (TXMD) Competitors

$2.11 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Atara Biotherapeutics (ATRA), Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Kalaris Therapeutics (KLRS), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry.

How does TherapeuticsMD compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential downside of 18.45%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Atara Biotherapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Atara Biotherapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
TherapeuticsMD	Neutral

Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Atara Biotherapeutics' net margin of -40.91%. TherapeuticsMD's return on equity of 0.32% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
TherapeuticsMD	5.34%	0.32%	0.23%

Atara Biotherapeutics has higher revenue and earnings than TherapeuticsMD. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.87	$32.69M	-$0.67	N/A
TherapeuticsMD	$3.35M	7.28	-$570K	$0.06	35.17

Summary

Atara Biotherapeutics and TherapeuticsMD tied by winning 7 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Biomea Fusion has a beta of -0.31, indicating that its share price is 131% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

In the previous week, Biomea Fusion's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Biomea Fusion	Neutral
TherapeuticsMD	Neutral

Biomea Fusion currently has a consensus target price of $8.50, indicating a potential upside of 502.84%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biomea Fusion is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
TherapeuticsMD	$3.35M	7.28	-$570K	$0.06	35.17

TherapeuticsMD has a net margin of 5.34% compared to Biomea Fusion's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
TherapeuticsMD	5.34%	0.32%	0.23%

Summary

TherapeuticsMD beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

How does TherapeuticsMD compare to Black Diamond Therapeutics?

TherapeuticsMD (NASDAQ:TXMD) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Black Diamond Therapeutics has a consensus price target of $9.83, suggesting a potential upside of 389.22%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Black Diamond Therapeutics has higher revenue and earnings than TherapeuticsMD. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.35M	7.28	-$570K	$0.06	35.17
Black Diamond Therapeutics	$70M	1.65	$22.37M	-$0.77	N/A

TherapeuticsMD has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market.

In the previous week, Black Diamond Therapeutics had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Black Diamond Therapeutics and 0 mentions for TherapeuticsMD. Black Diamond Therapeutics' average media sentiment score of 0.68 beat TherapeuticsMD's score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Black Diamond Therapeutics	Positive

TherapeuticsMD has a net margin of 5.34% compared to Black Diamond Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

Summary

Black Diamond Therapeutics beats TherapeuticsMD on 11 of the 17 factors compared between the two stocks.

How does TherapeuticsMD compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Kalaris Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Kalaris Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
TherapeuticsMD	5.34%	0.32%	0.23%

Kalaris Therapeutics currently has a consensus price target of $15.60, indicating a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Kalaris Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kalaris Therapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
TherapeuticsMD	Neutral

TherapeuticsMD has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
TherapeuticsMD	$3.35M	7.28	-$570K	$0.06	35.17

Summary

TherapeuticsMD beats Kalaris Therapeutics on 8 of the 14 factors compared between the two stocks.

How does TherapeuticsMD compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Cognition Therapeutics currently has a consensus price target of $3.33, indicating a potential upside of 184.90%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cognition Therapeutics is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cognition Therapeutics has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Cognition Therapeutics' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
TherapeuticsMD	5.34%	0.32%	0.23%

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

TherapeuticsMD has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
TherapeuticsMD	$3.35M	7.28	-$570K	$0.06	35.17

In the previous week, Cognition Therapeutics had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Cognition Therapeutics and 0 mentions for TherapeuticsMD. Cognition Therapeutics' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Cognition Therapeutics	Neutral
TherapeuticsMD	Neutral

Summary

Cognition Therapeutics and TherapeuticsMD tied by winning 7 of the 14 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.42M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	35.17	20.06	28.02	24.70
Price / Sales	7.28	360.34	540.55	99.42
Price / Cash	45.23	57.49	49.26	57.09
Price / Book	0.91	4.32	10.96	6.46
Net Income	-$570K	$64.45M	$3.57B	$337.01M
7 Day Performance	N/A	2.97%	2.12%	1.69%
1 Month Performance	6.03%	6.83%	5.25%	3.81%
1 Year Performance	88.39%	29.07%	33.29%	23.90%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	0.9851 of 5 stars	$2.11 flat	N/A	+88.4%	$24.42M	$3.35M	35.17	420	Gap Up
ATRA Atara Biotherapeutics	0.6981 of 5 stars	$11.48 +2.8%	$9.50 -17.2%	+45.4%	$100.64M	$120.77M	N/A	330
BMEA Biomea Fusion	1.9466 of 5 stars	$1.47 +5.8%	$8.50 +478.2%	-14.8%	$100.50M	N/A	N/A	50	Analyst Downgrade Gap Down
BDTX Black Diamond Therapeutics	3.7416 of 5 stars	$1.85 +5.7%	$9.83 +431.5%	-22.1%	$100.28M	$70M	N/A	90	Positive News
KLRS Kalaris Therapeutics	3.5397 of 5 stars	$4.07 -3.6%	$15.60 +283.3%	+90.0%	$100.28M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

How does TherapeuticsMD compare to Atara Biotherapeutics?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Summary

How does TherapeuticsMD compare to Black Diamond Therapeutics?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. ATRA, BMEA, BDTX, KLRS, and CGTX

How does TherapeuticsMD compare to Atara Biotherapeutics?

Do analysts recommend ATRA or TXMD?

Does the media refer more to ATRA or TXMD?

Which has more volatility & risk, ATRA or TXMD?

Do institutionals and insiders believe in ATRA or TXMD?

Is ATRA or TXMD more profitable?

Which has better earnings & valuation, ATRA or TXMD?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Do institutionals & insiders believe in BMEA or TXMD?

Which has more volatility and risk, BMEA or TXMD?

Does the media refer more to BMEA or TXMD?

Do analysts recommend BMEA or TXMD?

Which has higher valuation & earnings, BMEA or TXMD?

Is BMEA or TXMD more profitable?

Summary

How does TherapeuticsMD compare to Black Diamond Therapeutics?

Do analysts recommend TXMD or BDTX?

Do insiders & institutionals have more ownership in TXMD or BDTX?

Which has better valuation and earnings, TXMD or BDTX?

Which has more risk & volatility, TXMD or BDTX?

Does the media favor TXMD or BDTX?

Is TXMD or BDTX more profitable?

Summary

How does TherapeuticsMD compare to Kalaris Therapeutics?

Which has more volatility and risk, KLRS or TXMD?

Is KLRS or TXMD more profitable?

Do analysts recommend KLRS or TXMD?

Do insiders & institutionals believe in KLRS or TXMD?

Does the media favor KLRS or TXMD?

Which has stronger valuation and earnings, KLRS or TXMD?

Summary

How does TherapeuticsMD compare to Cognition Therapeutics?

Do analysts prefer CGTX or TXMD?

Which has more risk and volatility, CGTX or TXMD?

Is CGTX or TXMD more profitable?

Do institutionals & insiders believe in CGTX or TXMD?

Which has higher earnings and valuation, CGTX or TXMD?

Does the media refer more to CGTX or TXMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools